Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Beard

Showing results (551-560 of 576) with videos related to

Pageof 58
Sort By:
European Urology Focus|July 30, 2017
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Clinical Genitourinary Cancer|March 15, 2018
Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk ScoreDarren R Feldman, Shirin Ardeshir-Rouhani-Fard, Patrick Monahan, et al.
Journal of Clinical Epidemiology|October 20, 2018
The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluationLeila Rooshenas, Lauren J Scott, Jane M Blazeby, et al.
Urologic Oncology|May 22, 2014
Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancerBrandon A Mahal, David R Ziehr, Ayal A Aizer, et al.
Journal of Geriatric Oncology|May 28, 2014
Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancerBrandon A Mahal, David R Ziehr, Ayal A Aizer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based ChemotherapyChunkit Fung, Howard D Sesso, Annalynn M Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset CancerM Eileen Dolan, Omar El Charif, Heather E Wheeler, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 13, 2025
Shear Stress Targeted Delivery of Nitroglycerin to Brain Collaterals Improves Ischaemic Stroke OutcomeMagdalena Litman, Sara Azarpeykan, Rebecca J Hood, et al.
Nature Medicine|January 19, 2024
The IDEAL framework for surgical robotics: development, comparative evaluation and long-term monitoringHani J Marcus, Pedro T Ramirez, Danyal Z Khan, et al.
Nature Medicine|January 31, 2024
Author Correction: The IDEAL framework for surgical robotics: development, comparative evaluation and long-term monitoringHani J Marcus, Pedro T Ramirez, Danyal Z Khan, et al.
Pageof 58

Showing results (551-560 of 576) with videos related to

Sort By:
Pageof 58
European Urology Focus|July 30, 2017
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Clinical Genitourinary Cancer|March 15, 2018
Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk ScoreDarren R Feldman, Shirin Ardeshir-Rouhani-Fard, Patrick Monahan, et al.
Journal of Clinical Epidemiology|October 20, 2018
The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluationLeila Rooshenas, Lauren J Scott, Jane M Blazeby, et al.
Urologic Oncology|May 22, 2014
Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancerBrandon A Mahal, David R Ziehr, Ayal A Aizer, et al.
Journal of Geriatric Oncology|May 28, 2014
Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancerBrandon A Mahal, David R Ziehr, Ayal A Aizer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based ChemotherapyChunkit Fung, Howard D Sesso, Annalynn M Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset CancerM Eileen Dolan, Omar El Charif, Heather E Wheeler, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 13, 2025
Shear Stress Targeted Delivery of Nitroglycerin to Brain Collaterals Improves Ischaemic Stroke OutcomeMagdalena Litman, Sara Azarpeykan, Rebecca J Hood, et al.
Nature Medicine|January 19, 2024
The IDEAL framework for surgical robotics: development, comparative evaluation and long-term monitoringHani J Marcus, Pedro T Ramirez, Danyal Z Khan, et al.
Nature Medicine|January 31, 2024
Author Correction: The IDEAL framework for surgical robotics: development, comparative evaluation and long-term monitoringHani J Marcus, Pedro T Ramirez, Danyal Z Khan, et al.
Pageof 58